Envista Holdings is caught in a tug of war. JP Morgan just upgraded the dental equipment maker. At the same time, short sellers have been aggressively building positions.
JP Morgan analyst Lilia-Celine Lozada upgraded NVST to Overweight on September 3. The price target rose to $32, up from $29. The stock trades at $27.59 — implying 16% upside to the new target.
The timing is notable. The upgrade arrives as the stock sits near one-month lows. It also comes despite — or perhaps because of — a sharp rise in bearish positioning. Barclays also holds an Overweight rating with a $32 target. Evercore ISI carries an Outperform with a $33 target. The consensus mean target is $30.79.
The bull case centres on Premium Implant revenue growth and recovering Challenger Implant sales. Analysts point to raised full-year core sales growth guidance of 3–4%. The bear case focuses on the August earnings miss at the EBIT line and flat EBITDA margin guidance of roughly 14%.
Short interest has climbed sharply. It now stands at 7.5% of free float, up 18% over the past week and up nearly 50% over the past month. That is a significant shift in positioning.
The pulses cite activist accumulation and margin concerns post-earnings as drivers. The August 5 earnings release saw a 2.1% one-day decline. Short sellers appear to have used the weakness as an entry point.
Cost to borrow has moved with short interest. It rose 62% week-on-week to 0.41%. That is still a low absolute level. Despite the recent tightening, the borrow market remains loose — availability stands at 681%, meaning roughly seven shares are available to borrow for every one already lent out. There is no squeeze risk on current metrics.
The put/call ratio sits at 0.94, near the 52-week high of 0.96. The 20-day average PCR is 0.90. Options positioning has shifted distinctly more bearish over the past two weeks, coinciding with the short interest build.
The ORTEX short score ticked up to 50.1 as of September 2, its highest level in the recent history shown. EPS momentum scores are strong — 85th percentile on a 30-day basis — which supports the analyst upgrade thesis.
The September 17 earnings date is the next inflection point. Short sellers and JP Morgan are now explicitly on opposite sides of the trade heading into it.
See the live data behind this article on ORTEX.
Open NVST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
